Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.68 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1581596 | 0.96 | MET (0.73) | METNQO2 | |
| SCHEMBL3089413 | 0.83 | MET (0.85) | METNQO2 | |
| SCHEMBL1317047 | 0.82 | MET (0.70) | METNQO2 | |
| SCHEMBL2474804 | 0.81 | MET (0.68) | METNQO2 | |
| SCHEMBL3087171 | 0.81 | MET (1.00) | METNQO2 | |
| SCHEMBL1581481 | 0.81 | MET (0.72) | METNQO2 | |
| SCHEMBL3090717 | 0.81 | MET (1.00) | MET | |
| SCHEMBL3101965 | 0.81 | MET (0.87) | METNQO2 | |
| SCHEMBL3102320 | 0.81 | MET (0.81) | METNQO2 | |
| SCHEMBL3092280 | 0.81 | MET (1.00) | METNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859547-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8557813-B2 | 2-benzylpyridazinone derivatives as met kinase inhibitors | MERCK PATENT GMBH (DE) | 2013-10-15 | — | — | US | disclosed |
| US-20130190311-A1 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| US-20100273796-A1 | 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273796-A1 | 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS | ERBB2, RET, MET | MET 3/4885NQO2 822/4885 |
| US-20130190311-A1 | Pyridazinone derivatives | MET, RET, ERBB2 | MET 1/4885NQO2 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.